Bio-Rad Laboratories, Inc. (BIO)
- Previous Close
281.02 - Open
283.12 - Bid --
- Ask --
- Day's Range
280.56 - 285.27 - 52 Week Range
261.59 - 473.50 - Volume
47,835 - Avg. Volume
206,346 - Market Cap (intraday)
8.048B - Beta (5Y Monthly) 0.88
- PE Ratio (TTM)
-- - EPS (TTM)
-21.81 - Earnings Date May 7, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
409.80
Bio-Rad Laboratories, Inc. manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets. It also designs, manufactures, markets, and supports test systems, informatics systems, test kits, and specialized quality controls for hospitals, diagnostic reference, transfusion, and physician office laboratories. The company offers its products through its direct sales force, as well as through distributors, agents, brokers, and resellers. Bio-Rad Laboratories, Inc. was founded in 1952 and is headquartered in Hercules, California.
www.bio-rad.comRecent News: BIO
Performance Overview: BIO
Trailing total returns as of 4/19/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: BIO
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: BIO
Valuation Measures
Market Cap
8.01B
Enterprise Value
7.81B
Trailing P/E
--
Forward P/E
25.25
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
3.07
Price/Book (mrq)
0.92
Enterprise Value/Revenue
2.92
Enterprise Value/EBITDA
-11.92
Financial Highlights
Profitability and Income Statement
Profit Margin
-23.86%
Return on Assets (ttm)
1.77%
Return on Equity (ttm)
-6.94%
Revenue (ttm)
2.67B
Net Income Avi to Common (ttm)
-637.32M
Diluted EPS (ttm)
-21.81
Balance Sheet and Cash Flow
Total Cash (mrq)
1.61B
Total Debt/Equity (mrq)
16.08%
Levered Free Cash Flow (ttm)
170.82M
Research Analysis: BIO
Analyst Price Targets
Fair Value
Analyst Recommendations
- Strong Buy
- Buy
- Hold
- Underperform
- Sell
Earnings
Research Reports: BIO
BIO: Lowering target price to $307.00
BIO-RAD LABORATORIES-A has an Investment Rating of HOLD; a target price of $307.000000; an Industry Subrating of Low; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Low; a Growth Subrating of Medium; and a Value Subrating of Medium.
RatingNeutralPrice TargetBIO: Raising target price to $356.00
BIO-RAD LABORATORIES-A has an Investment Rating of HOLD; a target price of $356.000000; an Industry Subrating of Low; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Low; a Growth Subrating of Medium; and a Value Subrating of Medium.
RatingNeutralPrice TargetBIO: Lowering target price to $345.00
BIO-RAD LABORATORIES-A has an Investment Rating of HOLD; a target price of $345.000000; an Industry Subrating of Low; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Low; a Growth Subrating of Medium; and a Value Subrating of Medium.
RatingNeutralPrice TargetBIO: Raising target price to $358.00
BIO-RAD LABORATORIES-A has an Investment Rating of HOLD; a target price of $358.000000; an Industry Subrating of Low; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Low; a Growth Subrating of Medium; and a Value Subrating of Medium.
RatingNeutralPrice Target